139 related articles for article (PubMed ID: 34145944)
21. Three-year denosumab treatment in postmenopausal Japanese women and men with osteoporosis: results from a 1-year open-label extension of the Denosumab Fracture Intervention Randomized Placebo Controlled Trial (DIRECT).
Sugimoto T; Matsumoto T; Hosoi T; Miki T; Gorai I; Yoshikawa H; Tanaka Y; Tanaka S; Fukunaga M; Sone T; Nakano T; Ito M; Matsui S; Yoneda T; Takami H; Watanabe K; Osakabe T; Okubo N; Shiraki M; Nakamura T
Osteoporos Int; 2015 Feb; 26(2):765-74. PubMed ID: 25403903
[TBL] [Abstract][Full Text] [Related]
22. Denosumab treatment lapses, discontinuation, and off-treatment fracture risk: A retrospective study of patients with osteoporosis in a real-world clinical setting.
Cruchelow KR; Peter ME; Chakrabarti A; Gipson HM; Gregory WT; DeClercq J; Choi L; Tanner SB
Bone; 2023 Dec; 177():116925. PubMed ID: 37797711
[TBL] [Abstract][Full Text] [Related]
23. Observations following discontinuation of long-term denosumab therapy.
McClung MR; Wagman RB; Miller PD; Wang A; Lewiecki EM
Osteoporos Int; 2017 May; 28(5):1723-1732. PubMed ID: 28144701
[TBL] [Abstract][Full Text] [Related]
24. Rebound-associated vertebral fractures after discontinuation of denosumab for the treatment of maxillitis.
Niimi R; Kono T; Nishihara A; Hasegawa M; Kono T; Sudo A
Osteoporos Int; 2018 Mar; 29(3):769-772. PubMed ID: 29230512
[TBL] [Abstract][Full Text] [Related]
25. Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-Switch study): extension of a randomised controlled trial.
Leder BZ; Tsai JN; Uihlein AV; Wallace PM; Lee H; Neer RM; Burnett-Bowie SA
Lancet; 2015 Sep; 386(9999):1147-55. PubMed ID: 26144908
[TBL] [Abstract][Full Text] [Related]
26. Fracture incidence after denosumab discontinuation: Real-world data from a large healthcare provider.
Tripto-Shkolnik L; Fund N; Rouach V; Chodick G; Shalev V; Goldshtein I
Bone; 2020 Jan; 130():115150. PubMed ID: 31715340
[TBL] [Abstract][Full Text] [Related]
27. Denosumab for prevention of fractures in postmenopausal women with osteoporosis.
Cummings SR; San Martin J; McClung MR; Siris ES; Eastell R; Reid IR; Delmas P; Zoog HB; Austin M; Wang A; Kutilek S; Adami S; Zanchetta J; Libanati C; Siddhanti S; Christiansen C;
N Engl J Med; 2009 Aug; 361(8):756-65. PubMed ID: 19671655
[TBL] [Abstract][Full Text] [Related]
28. Fractures After Denosumab Discontinuation: A Retrospective Study of 797 Cases.
Burckhardt P; Faouzi M; Buclin T; Lamy O;
J Bone Miner Res; 2021 Sep; 36(9):1717-1728. PubMed ID: 34009703
[TBL] [Abstract][Full Text] [Related]
29. Alendronate after denosumab discontinuation in women previously exposed to bisphosphonates was not effective in preventing the risk of spontaneous multiple vertebral fractures: two case reports.
Lamy O; Fernández-Fernández E; Monjo-Henry I; Stoll D; Aubry-Rozier B; Benavent-Núñez D; Aguado P; Gonzalez-Rodriguez E
Osteoporos Int; 2019 May; 30(5):1111-1115. PubMed ID: 30613866
[TBL] [Abstract][Full Text] [Related]
30. A Single Infusion of Zoledronate in Postmenopausal Women Following Denosumab Discontinuation Results in Partial Conservation of Bone Mass Gains.
Everts-Graber J; Reichenbach S; Ziswiler HR; Studer U; Lehmann T
J Bone Miner Res; 2020 Jul; 35(7):1207-1215. PubMed ID: 31991007
[TBL] [Abstract][Full Text] [Related]
31. Vertebral fracture assessment by dual-energy X-ray absorptiometry along with bone mineral density in the evaluation of postmenopausal osteoporosis.
Shetty S; John B; Mohan S; Paul TV
Arch Osteoporos; 2020 Feb; 15(1):25. PubMed ID: 32095943
[TBL] [Abstract][Full Text] [Related]
32. Vertebral fractures cascade: potential causes and risk factors.
Che H; Breuil V; Cortet B; Paccou J; Thomas T; Chapuis L; Debiais F; Mehsen-Cetre N; Javier RM; Loiseau Peres S; Roux C; Briot K
Osteoporos Int; 2019 Mar; 30(3):555-563. PubMed ID: 30519756
[TBL] [Abstract][Full Text] [Related]
33. Risk factors for vertebral fractures and bone loss after denosumab discontinuation: A real-world observational study.
Everts-Graber J; Reichenbach S; Gahl B; Ziswiler HR; Studer U; Lehmann T
Bone; 2021 Mar; 144():115830. PubMed ID: 33359006
[TBL] [Abstract][Full Text] [Related]
34. Severe spontaneous vertebral fractures after denosumab discontinuation: three case reports.
Aubry-Rozier B; Gonzalez-Rodriguez E; Stoll D; Lamy O
Osteoporos Int; 2016 May; 27(5):1923-5. PubMed ID: 26510845
[TBL] [Abstract][Full Text] [Related]
35. Remarkable loss of bone mineral density in 6 months after denosumab discontinuation: a case report.
Maezumi Y; Kamimura M; Nakamura Y; Takahashi J
Mod Rheumatol Case Rep; 2020 Jul; 4(2):218-221. PubMed ID: 33087002
[TBL] [Abstract][Full Text] [Related]
36. Dilemma of denosumab therapy: rebound fractures with denosumab cessation or dose delay.
Herath M; Wong P; Milat F
Intern Med J; 2021 Feb; 51(2):297-298. PubMed ID: 33631850
[No Abstract] [Full Text] [Related]
37. Prevalent vertebral fractures and minor vertebral deformities analyzed by vertebral fracture assessment (VFA) increases the risk of incident fractures in postmenopausal women: the FRODOS study.
Kanterewicz E; Puigoriol E; Rodríguez Cros JR; Peris P
Osteoporos Int; 2019 Oct; 30(10):2141-2149. PubMed ID: 31123788
[TBL] [Abstract][Full Text] [Related]
38. Suboptimal medication adherence may favor the progression of vertebral fractures in women with post-menopausal osteoporosis treated with denosumab.
Betella N; Biamonte E; Matarazzo C; Piccini S; Olivetti R; Cellini M; Lania AG; Mazziotti G
Minerva Endocrinol; 2020 Sep; 45(3):165-171. PubMed ID: 32186164
[TBL] [Abstract][Full Text] [Related]
39. [Multiple vertebral fractures after denosumab discontinuation].
Tjelum L; Eiken P
Ugeskr Laeger; 2018 Nov; 180(45):. PubMed ID: 30404716
[TBL] [Abstract][Full Text] [Related]
40. Sixty spontaneous vertebral fractures after denosumab discontinuation in 15 women with early-stage breast cancer under aromatase inhibitors.
Gonzalez-Rodriguez E; Aubry-Rozier B; Stoll D; Zaman K; Lamy O
Breast Cancer Res Treat; 2020 Jan; 179(1):153-159. PubMed ID: 31598815
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
